Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Viral ToxGlo™ Assay

Instructions for Use of Product(s)
G8941, G8942, G8943

Literature # TM393

The Viral ToxGlo™ Assay is a homogeneous, add-mix-measure method intended for use in research studies to identify cytopathic effect (CPE) induced by viral infection. The assay measures cellular ATP, a stable and tightly regulated surrogate of cell viability. Luminescent signals from the assay are proportional to viable cell number. When CPE occurs due to viral infection, ATP depletion can be measured and correlated with viral burden. Notably, this method is useful only for viruses that produce cytotoxicity and CPE.
The assay can be used in two principal ways. First, viral infectivity and the corresponding tissue culture infective dose (TCID) can be determined by serially diluting a virus preparation and applying it to target cell line(s) for a specified exposure period. The virus dilution that produces a cytotoxic endpoint effect (i.e., TCID50 or 50% CPE) can be calculated and used for subsequent studies. Secondly, a known excess of virus (i.e., 100 TCID50 or 100X the TCID50) can be delivered to cells with test compounds and incubated to determine potential antiviral effects. The latter application can be conducted in either single-dose high-throughput screens (HTS) or as part of a full-compound dose-response series (qHTS).

Summary of Change
The following change was made to the 2/15 revision of this document:
Removed a duplicate step in Section 3.C Protocol for Determining Antiviral Potency.

Printed in USA. Revised 2/15